Purple Biotech shareholders approve all AGM items

Available on EDGAR 09/09/2026 - 04:02 PM EDT Accepted by SEC EDGAR 09/09/2026 - 04:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

PURPLE BIOTECH LTD. (PPBT) reports that all proposals presented at its Annual General Meeting of Shareholders, held on September 8, 2026 in Rehovot, Israel, were approved by the required shareholder majorities in accordance with Israeli Companies Law and the company’s articles of association.

The company also states that this report on Form 6-K, including its exhibits, is incorporated by reference into multiple previously filed registration statements on Forms S-8 and F-3, so it becomes part of those registration statements from the submission date.

Key Terms

Annual General Meeting of Shareholders, Israeli Companies Law, 5759-1999, incorporated by reference, Registration Statement on Form F-3, +1 more

5 terms

Annual General Meeting of Shareholders financial

"announcing the results of the Annual General Meeting of Shareholders of the Company"

Israeli Companies Law, 5759-1999 regulatory

"approved by the requisite vote of the Company’s shareholders in accordance with the Israeli Companies Law, 5759-1999"

incorporated by reference regulatory

"is hereby incorporated by reference into each of the Registrant’s Registration Statement"

Registration Statement on Form F-3 financial

"the Registrant’s Registration Statement on Form F-3, as amended, originally filed"

A registration statement on Form F-3 is a streamlined filing used by eligible foreign companies to register securities for sale in the U.S., often as a “shelf” that lets them offer shares quickly when market conditions are right. For investors it matters because it signals that the company can raise capital on short notice—potentially increasing liquidity but also the risk of share dilution if new stock is issued—similar to a company keeping a pre-approved credit line ready to use.

Registration Statement on Form S-8 financial

"the Registrant’s Registration Statement on Form S-8 filed with the Securities"

A registration statement on Form S-8 is the U.S. Securities and Exchange Commission filing companies use to register shares they intend to grant to employees, directors, consultants or benefit plans under stock compensation programs. It matters to investors because it signals potential issuance of new shares tied to pay and incentives, which can increase the total shares outstanding — like adding more slices to a pie — reducing each existing share’s ownership and potentially affecting earnings per share and stock value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PURPLE BIOTECH LTD. (PPBT) announce in this Form 6-K?

The company announced that all proposals at its Annual General Meeting of Shareholders held on September 8, 2026 were approved by the requisite shareholder vote under Israeli Companies Law and its articles of association.

When did PURPLE BIOTECH LTD. (PPBT) hold its 2026 Annual General Meeting?

Purple Biotech Ltd. held its 2026 Annual General Meeting of Shareholders on September 8, 2026 at the company’s offices in Rehovot, Israel.

Were the shareholder proposals at PPBT’s 2026 Annual General Meeting approved?

Yes. The company states that each proposal presented for approval at the September 8, 2026 meeting was approved by the requisite vote of shareholders in accordance with Israeli Companies Law and the company’s articles of association.

How does this Form 6-K affect PPBT’s existing registration statements?

Purple Biotech Ltd. states that this Form 6-K, including all exhibits, is incorporated by reference into multiple existing registration statements on Forms S-8 and F-3, making it part of those filings from the date of submission.

Which SEC forms are mentioned as incorporating this PPBT Form 6-K by reference?

The company lists several registration statements on Form S-8 and Form F-3, including file numbers 333-211478, 333-218538, 333-230584, 333-233795, 333-238229, 333-238481, 333-239807, 333-233793, 333-264107, 333-268710 and 333-270769.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of September 2026

Commission File Number: 001-37643

PURPLE BIOTECH LTD.

(Translation of registrant’s name into English)

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. 

Form 20-F ☒     Form 40-F ☐

Purple Biotech Ltd. (the “Company” or the “Registrant”) is announcing the results of the Annual General Meeting of Shareholders of the Company held on September 8, 2026, at the Company’s offices (the “Meeting”). At the Meeting, the shareholders of the Company voted on the proposals described in the Company’s Proxy Statement for the Meeting that was attached as Exhibit 99.1 to a Report of Foreign Private Issuer on Form 6-K furnished by the Company to the U.S. Securities and Exchange Commission on July 29, 2026 (the “Proxy Statement”).

Each of the proposals presented for approval at the Meeting was approved by the requisite vote of the Company’s shareholders in accordance with the Israeli Companies Law, 5759-1999 and the Company’s articles of association, as described in the Proxy Statement.

Incorporation by Reference

This Report on Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333-238229), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 18, 2020 (Registration file number 333-238481), each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 10, 2020 (Registration file numbers 333-239807 and 333-233793), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 4, 2022 (Registration file number 333-264107), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on December 8, 2022 (Registration file number 333-268710), and the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on March 23, 2023 (Registration file number 333-270769), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

September 9, 2026	PURPLE BIOTECH LTD.
	By:	/s/ Shai Lankry
		Shai Lankry
		Chief Financial Officer

2